A path forward towards accelerating cervical cancer eradication

Diana SM Buist, PhD, MPH
Senior Scientific Investigator, Kaiser Permanente Washington Health Research Institute
Professor, Kaiser Permanente Bernard J. Tyson School of Medicine

Affiliate Professor, University of Washington, School of Public Health, Departments of Epidemiology and Health Systems and Population Health

@dianabuist

Disclosures

- Funded by: NCI, AHRQ, PCORI and CDC
  - Co-I on Completed NCI trial: Home-Based Options to Make Cervical Cancer Screening Easy (HOME) trial NCT02005510 (R01 CA168598)

    Clinical outcomes in underscreened females
  - PI on NCI trial Self-Testing Options in the Era of Primary HPV Screening for Cervical Cancer Trial (STEP) - NCT04679675 (R01 CA240375)

    Screening uptake and completion by different outreach strategies stratified by screening history

- Employed by Kaiser Foundation Health Plan of Washington





Achieving the 90-70-90 targets by 2030 would result in over 62 million cervical cancer deaths averted by 2120.



Cancer Prevention through Vaccination with Long Sojourn time



US population of females aged 30-64

73,180,000

18,295,000

14,000

50%


fear
bodyimage
time
childcare
inconvenience
knowledge
transportation
financial
distance
cultural
work

Percent up-to-date with cervical cancer screening by insurance status in the US



https://www.ncqa.org/hedis/measures/cervical-cancer-screening/





	Mailed HPV Kit	Usual Care	RR (95% CI)
Screening initiation	2646 (26.6%)	1917 (17.4%)	1.53 (1.45-1.61)
Screening completed	2618 (26.3%)	1917 (17.4%)	1.51 (1.43-1.60)

JAMA Netw Open 2019

NCT02005510 (R01 CA168598)



Colposcopy needed

In-clinic testing

Home test negative, screening complete

JAMA Netw Open 2019

NCT02005510 (R01 CA168598)

NCT04679675 (R01 CA240375)

Instructions for Your Cervical Cancer Screening Kit

KAISER PERMANENTE®

Please do not use this kit if you are pregnant.



STEP 1



STEP 2



STEP 3



STEP 4

JOURNAL OF WOMEN'S HEALTH
Volume 00, Number 00, 2018

DOI: 10.1089/jwh.2018.7070

Understanding Patients' Perspectives and Information Needs Following a Positive Home Human Papillomavirus Self-Sampling Kit Result

Jasmin A. Tiro, PhD,[1] Andrea C. Betts, MPH,[1,2] Kilian Kimbel, BA,[3] Diana S.M. Buist, PhD,[3] Constance Mao, MD,[4] Hongyuan Gao, MS,[3] Lisa Shulman, MSW,[3] Colin Malone, MPH,[5] Tara Beatty, MA,[3] John Lin, BA,[6] Chris Thayer, MD,[7] Diana L. Miglioretti, PhD,[3,8] and Rachel L. Winer, PhD[3,5]

Reactions of women underscreened for cervical cancer who received unsolicited human papillomavirus self-sampling kits

J Med Screen
2020, Vol. 27(3) 146–156

DOI: 10.1177/0969141319885994
journals.sagepub.com/home/msc
SAGE

Colin Malone[1], Jasmin A Tiro[2], Diana SM Buist[3], Tara Beatty[3], John Lin[1], Kilian Kimbel[3], Hongyuan Gao[3], Chris Thayer[4], Diana L Miglioretti[3,5] and Rachel L Winer[1,3]

NCT02005510
R01 CA168598

Self-Testing options in the Era of Primary HPV screening for cervical cancer STEP Trial



NCT04679675 (R01 CA240375) Clinical Trial: NCT04679675 (Buist/Winer)

International Journal of Women's Health

Dovepress
open access to scientific and medical research

Open Access Full Text Article

REVIEW

Cervical Cancer Screening Postpandemic: Self-Sampling Opportunities to Accelerate the Elimination of Cervical Cancer

Taja Lozar[1–3]
Rahul Nagvekar[4]
Charles Rohrer[5]
Racheal Shamiso Dube Mandishora[6,7]
Urska Ivanus[3,8,9]
Megan Burke Fitzpatrick[1,5]

Comment on this paper

Relative Sensitivity of ID NOW and RT-PCR for Detection of SARS-CoV-2 in an Ambulatory Population: Clinical Evaluation, Systematic Review and Meta-analysis

Yuan-Po Tu, Jameel Iqbal, Timothy O'Leary

doi: https://doi.org/10.1101/2020.12.07.20245225

Now published in *eLife* doi: 10.7554/eLife.65726



Taplin et al
***CEBP* 2012**

Recommendations

- Learn from COVID
  - ✓ Primary prevention & education: What has worked to address vaccine hesitancy, how have complex scientific concepts been relayed to the public
  - ✓ Self-collection: increase validation and implementation evaluations
  - ✓ Speed
- Multi-everything
  - ✓ Multi-level, multi-site, multi-modalities (mixed methods), multi-lingual & multi-cultural
- Invest in training for researchers to communicate to various stakeholders
- Reform NIH funding paradigm
  - ✓Faster
  - ✓Innovative funding mechanisms (e.g., UG3-UH3; NIDDK PAR-20-160)


Thank you
@dianabuist